Inactive Instrument
Company Progenics Pharmaceuticals, Inc.
Stocks
US7431871067
Biotechnology & Medical Research
Business description: Progenics Pharmaceuticals, Inc.
Sales by Activity: Progenics Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) |
|---|---|
Pharmaceuticals | 34.99M |
Executive Committee: Progenics Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
Company details: Progenics Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.86% | -0.26% | +51.45% | +110.98% | 54.92B | |
| -0.34% | +3.51% | +45.55% | +40.16% | 44.31B | |
| +0.29% | +6.20% | -14.80% | -19.65% | 22.96B | |
| -0.40% | +3.49% | -1.29% | +387.06% | 21.12B | |
| -3.43% | -0.27% | +12.68% | -37.07% | 16.31B | |
| -1.54% | -1.06% | +7.63% | -39.28% | 15.19B | |
| -0.24% | +2.44% | +27.43% | +177.49% | 13.32B | |
| +1.29% | +9.60% | +19.07% | - | 12.48B | |
| +0.32% | +2.81% | +96.37% | +213.49% | 11.21B | |
| Average | -0.77% | +2.75% | +27.12% | +104.15% | 23.54B | |
| Weighted average by Cap. | -1.12% | +2.86% | +30.61% | +96.09% |
